Copy
CTT Pharmaceutical Holdings Files Patent Continuation for Enhanced Protection
August 18, 2026 — Leads & Copy — CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) has filed a patent continuation with the United States Patent Office, seeking to broaden its intellectual property protection. The application is a continuation of the company's existing U.S. patent for its micelle technology.
CTT Pharma intends to continue strengthening its patent portfolio and will provide updates to shareholders regarding any new patent information as it becomes available.
CTT Pharmaceutical Holdings, Inc. is a pharmaceutical technology company that develops oral drug delivery systems. These systems are designed to achieve rapid onset of action, improve patient convenience, and ensure efficient absorption of therapeutic substances. The company's patented micelle-based thin film platform aims to serve as a novel alternative to conventional dosage forms within the pharmaceutical, therapeutic, and nutraceutical sectors.
The company's strategic focus includes integrating scientific validation, enabling scalable manufacturing processes, and ensuring regulatory compliance to foster sustained growth and drive product innovation.